Skip to main content
Caplight Logo









Oculogenex

Oculogenex

Private
La Habra, CaliforniaHealthcare & Life Scienceshttps://oculogenex.com/

Last Round

Grant

May 1, 2022

Total Funding Raised

$1.28M

Company Overview

Oculogenex is a biotechnology company developing a regenerative gene therapy to treat retinal disorders such as dry age-related macular degeneration.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Space Technology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyage-related macular degenerationAMDretinal diseaseAAVadeno-associated viral vectorsregenerative medicinegeographic atrophybiotech startupocular therapyspace-based researchdrug discoveryretinal stem cellsprecision medicineeye health tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oculogenex Comparables

Compare Oculogenex with similar companies based on industry and business-model similarity.

Oculogenex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Perceive Biotherapeutics, Inc.
84%
Complement Therapeutics GmbH
82%
Beacon Therapeutics
81%

Oculogenex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 1, 2022
GrantOct 28, 2021
GrantMay 1, 2021
GrantFeb 6, 2021

Key People

Founding team and executive leadership

FASRS Hema Ramkumar

Chief Executive Officer

Executive Team

Ram Ramkumar

Chief Operating Officer

Executive Team

Oculogenex Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2022

    Received $1M grant from the National Science Foundation.

  • Nov 2, 2021

    Received grant funding from Boeing and MassChallenge.

Oculogenex Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oculogenex Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oculogenex's valuation, stock price, and market status.

Firmographic Details

HeadquartersLa Habra, California
Employee Range4
Year Founded2020
Last FundingMay 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?